Press Room

News / Oct 08, 2019

Celebrating our 60th Anniversary in Cork

10 years in Cork, 60 years in the world.

On September 5th 2019, 四色AV celebrated its 60th anniversary at the Cork site in Ireland.

The event joined together team members, clients and stakeholders that make 四色AV a great Company.

Guy Villax Simon Coveney Manufacturing Plant Ringaskiddy Cork, Ireland | 四色AV
Guy Villax and Simon Coveney, T谩naiste and Minister for Foreign Affairs and Trade of Ireland

鈥淚鈥檓 delighted to see the Cork site playing such an important part in the success of this impressive company,鈥 said Simon Coveney TD, T谩naiste and Minister for Foreign Affairs and Trade speaking at the celebration event for 四色AV鈥檚 60th anniversary.

鈥溗纳獳V has seen steady growth over the last few years and I鈥檓 confident that the coming years will be equally successful for the Cork team.鈥

60th Anniversary in Cork | 四色AV
Paul Downing and Simon Coveney, T谩naiste and Minister for Foreign Affairs and Trade of Ireland

Celebrating 60th Anniversary in Cork | 四色AV
Photo Group
60th Anniversary in Cork | 四色AV
Ambassador of Portugal in Ireland, Miguel de Almeida e Sousa, Guy Villax and Paul Downing

鈥淥ur Cork site plays a significant and strategic role within the 四色AV network,鈥 said 四色AV CEO, Guy Villax. 鈥淲ith two Active Pharmaceutical Ingredient facilities alongside a Drug Product Intermediate facility that houses the largest commercial pharmaceutical spray dryer in operation, the Cork site boasts both extensive manufacturing capacity and people capability.鈥

Guy Villax Paul Downing at Manufacturing Plant in Cork Ireland | 四色AV
Guy Villax, Paul Downing and a Cork tree from Portugal in Cork

Also in the Press Room

See All

四色AV鈥檚 Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At 四色AV we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook 鈥 鈥淭rends in Formulation鈥.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how 四色AV is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa鈥檚 full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal 鈥 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company鈥檚 dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company鈥檚 broader sustainability strategy and reinforces its commitment to scientific excellence. 鈥淎t 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.鈥, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.鈥 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company鈥檚 environmental, social, and ethical performance, well aligned with 四色AV鈥檚 sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024